< 1 minute read
Sep. 15, 2021

WF-47-JS03: An oral in vivo RET kinase inhibitor

WF-47-JS03

RET kinase inhibitor orally efficacious in XG but narrow TI from data mining of internal matter and opt. ACS Med. Chem. Lett. Feb. 12, 2020 Novartis (GNF), San Diego, CA

drughunter.com
Drug Hunter Team

(Novartis (GNF) oral in vivo RET kinase inhibitor)

Loading...

twitterlinkedinemail

Other molecules you may be interested in